Chardan Capital Markets initiated coverage on Stoke Therapeutics with a new price target
$STOK
Biotechnology: Pharmaceutical Preparations
Health Care
Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00